Aspirin resistance in patients with ventricular assist devices: A follow‐up study
Artificial Organs · 2024
DOI: 10.1111/aor.14742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2024. Verfasst von Tobias Flieder und 9 weiteren Autor:innen. Beteiligte Einrichtung: Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriums- und Transfusionsmedizin, B…. Hauptthemen laut MEDLINE: Heart-Assist Devices, Aspirin, Platelet Aggregation Inhibitors, Drug Resistance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Despite combined anticoagulation therapy consisting of a vitamin K antagonist and an antiplatelet agent, thromboembolic complications often occur in patients with a left ventricular assist device (LVAD). In addition, bleeding events are also common. Resistance to antiplatelet drugs is a well‐known phenomenon; however, the utilization of laboratory chemistry testing for the presence of such resistance, and then switching therapy, is controversial.
Methods
We tested 132 patients with LVAD (HeartWare n = 57, HeartMate II n = 22, HeartMate 3 n = 53) on acetylsalicylic acid (ASA) therapy for resistance and followed them for a maximum of 7 years regarding pump thrombosis. Light transmission aggregometry (LTA) and impedance aggregometry (IPA) were performed for testing platelet function.
Results
We could show that patients with ASA resistance displayed an increased risk of pump thrombosis, regardless of the test used (LTA: OR = 6.20, CI [1.86–20.64], p = 0.003; IPA: OR = 12.14, CI [3.00–49.07], p < 0.001). In patients with a HeartMate 3, we could not detect any pump thrombosis associated with aspirin resistance. Furthermore, there was no significant difference in bleeding events between patients with ASA resistance and ASA responders.
Conclusion
Laboratory testing of ASA resistance seems to be a good tool to detect an increased risk of pump thrombosis, at least for patients with a HeartWare or HeartMate II. The extent to which these thromboses can be prevented with a change of medication has to be investigated in further studies. No pump thrombosis was detected in patients with a HeartMate 3, and the question should be asked as to what constellation of underlying and concomitant diseases must be present to justify ASA therapy for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriums- und Transfusionsmedizin, Bad Oeynhausen, Germany.
- Institut für Psychosoziale Medizin, Psychotherapie und Psychoonkologie, Universitätsklinikum Jena, Friedrich-Schiller-Universität, Jena, Germany.
- Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Klinik für Thorax- und Kardiovaskularchirurgie, Bad Oeynhausen, Germany.
ORCID-Profile: Ingvild Birschmann
Zitieren
APA
Flieder, T., Blaesen, S., Schulte, K., Blasberg, J., Lauenroth, V., Knabbe, C., Schramm, R., Morshuis, M., Gummert, J., & Birschmann, I. (2024). Aspirin resistance in patients with ventricular assist devices: A follow‐up study. Artificial Organs. https://doi.org/10.1111/aor.14742
Vancouver
Flieder T, Blaesen S, Schulte K, Blasberg J, Lauenroth V, Knabbe C, et al. Aspirin resistance in patients with ventricular assist devices: A follow‐up study. Artificial Organs. 2024. doi:10.1111/aor.14742
BibTeX
@article{Flieder2024,
author = {Flieder, Tobias and Blaesen, Sonja and Schulte, Katrin and Blasberg, Jost and Lauenroth, Volker and Knabbe, Cornelius and Schramm, René and Morshuis, Michiel and Gummert, Jan and Birschmann, Ingvild},
title = {Aspirin resistance in patients with ventricular assist devices: A follow‐up study},
journal = {Artificial Organs},
year = {2024},
doi = {10.1111/aor.14742}
}
EUVIMED